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ABSTRACT
Background: Adipose tissue produces many metabolically active substances such as adiponectin and visfa-
tin. Both have potential anti-inflammatory, anti-atherogenic, and increasing insulin sensitivity properties. We 
evaluated the diagnostic value of serum adiponectin and visfatin as potential cardiometabolic risk factors. 
Subjects and methods: Sixty non-smoking, non-obese subjects aged 25–40 years with normal fasting 
glycaemia were included in the study. In all subjects serum fasting lipid profile, CRP, glucose, insulin, 
and apolipoprotein AI and B measurements were performed on an automatic analyser, while adiponectin 
and visfatin were measured using manual enzyme-linked immunosorbent assay (ELISA). Blood pressure 
measurements, body composition analysis using bioimpedance method (BIA), and basic anthropometric 
measurements (weight, BMI, WHR) were performed. 
Results: In the study group the concentration of adiponectin and visfatin was significantly inversely and moder-
ately related with the amount of visceral fat, BMI, and waist circumference, while an inverse weak relationship 
with HOMA-IR and insulin level was observed. Moreover, adiponectin was weakly inversely related with CRP 
but positively with HDL-C and apolipoprotein AI. The prevalence of subjects with CRP < 1 mg/L was signifi-
cantly higher at the highest adiponectin and visfatin concentrations (third tertile). At the lowest adiponectin 
concentrations (first tertile) the percentage of subjects with elevated apoB ≥ 100 mg/dL was increased.
Conclusion: The relationship of serum adiponectin and visfatin with the amount of visceral fat, lipid profile, 
apolipoproteins, and CRP suggests their potential diagnostic value in the assessment of cardiometabolic 
risk. The predictive value of both adipocytokines should be confirmed in a large population-based study.
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Introduction
According to the World Health Organisation, in 
2005 around 1.6 billion people worldwide were over-
weight and more than 522 million were obese. Obesity 
is not only a medical problem, contributing to about 10-
13% of premature deaths in Europe, but also economic 
problem. Costs related to the diagnosis and treatment 
of obesity in Europe range from 2 to 7% of financial 
outlays for health care [1]. In recent decades, research 
on adipose tissue has revealed a number of findings 
that have allowed adipose tissue to be qualified as an 
endocrine organ. The discovery of leptin in 1994 was 
a breakthrough. Since then, many other substances de-
rived from adipose tissue have been isolated, including 
adipocytokines, various cytokines, and proteins. 
Particularly important is the role of adipocytes in 
the production of adipocytokines and cytokines that 
regulate systemic inflammation. These indicators are 
used in routine diagnostics of inflammation and in-
fection. The most important markers of inflammation 
released from adipose tissue include: TNF-a, Il-6, Il-1b, 
and procalcitonin (PCT). Adipocytokines exhibit local 
and systemic pro- and anti-inflammatory effects. They 
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regulate metabolic and systemic processes and play 
a role in maintaining energy balance in glucose and 
lipid metabolism. They also participate in immune 
mechanisms and affect angiogenesis.
Numerous studies have confirmed a strong relation-
ship between type 2 diabetes, metabolic syndrome, and 
cardiometabolic risk with changes in the level of adipo-
cytokines. Among the most well-known adipocytokines 
are adipsin, leptin, adiponectin, resistin, and visfatin. 
In 2005, the gene for growth factor for early B cells 
(B-cell colony-enhancing factor, PBEF) was identified 
in visceral adipose tissue, and the product of this gene 
was called visfatin. Visfatin (PBEF, NAMPT) is a peptide 
composed of 491 amino acids [2]. It is produced in 
adipocytes and macrophages infiltrating adipose tissue 
and in some cancer cells. Secretion of visfatin fluctuatES 
throughout the day with the highest concentration ob-
served in the afternoon. Visfatin exerts a hypoglycaemic 
effect, which is because PBEF directly binds to the in-
sulin receptor at a site other than insulin and promotes 
glucose uptake in tissues. Visfatin induces the process 
of differentiation of preadipocytes to adipocytes, and 
further stimulates the synthesis of proinflammatory 
cytokines, including Il-6 and Il-8. Its concentration is 
related to the level of oxidative stress [3]. 
Adiponectin composed of 244 amino acids consti-
tutes about 0.01% of all plasma proteins. In women, 
its concentration is higher than in men [4]. It exhibits 
structural similarity to collagen type VIII and X, as well as 
to the complement fraction C1q. In blood, adiponectin 
occurs in three forms, differing in molecular weight: low 
molecular weight (trimer) — lMW, medium molecular 
weight (hexamer) — MMW, and high-molecular weight 
(built from 12-14 subunits) — HMW.
Adiponectin is derived primarily from adipocytes, 
but in small amounts from bone marrow cells, endo-
thelial cells of the liver, and cardiomyocytes, and it is 
metabolised in the kidneys. Adiponectin is involved 
in many processes: organogenesis, inflammation, 
glucose metabolism, cell differentiation, and auto-
immune reactions [5]. Adiponectin was proven to 
enhance insulin sensitivity by several mechanisms: 
increasing the oxidation and transport of free fatty 
acids, lowering blood glucose by reducing liver glu-
coneogenesis, inhibition of triglyceride deposition 
in adipose tissue, and decreasing TNF-a activity in 
adipose tissue and in macrophages located in the 
vascular endothelium [6]. Decreased adiponectin 
levels are observed in obesity, cardiovascular dis-
eases, in subjects with insulin resistance, as well as in 
in alcoholics and smokers [5]. 
We evaluated the relationship between serum adi-
ponectin and visfatin concentration with body compo-
sition and various biochemical cardiometabolic risk fac-
tors in young non-obese normoglycaemic individuals.
Subjects, materials, and methods
The study consisted of 60 non-obese (BMI < 30 kg/m2), 
non-smoking, and normoglycaemic (fasting glucose 
60–99 mg/dl) subjects aged 25–40 years (30 women, 
30 men). Basic anthropometric measurements (body 
weight, waist circumference, BMI, WHR) and blood 
pressure measurements with an automatic blood pres-
sure monitor Omron M6 Comfort (Omron Healthcare, 
Kyoto, Japan) were performed and medical history of 
chronic diseases was obtained.
Serum and fluoride plasma were collected in the 
morning (7.00-9.00 a.m.) after 12-hour fast. Samples 
were centrifuged in low temperature (4°C). laboratory 
tests: glucose, C-reactive protein (CRP), total cho-
lesterol (TC), HDl-cholesterol (HDl-C), triglycerides 
(TG), and apolipoproteins AI and B (apoAI, apoB) were 
performed on an Architect ci8200 (Abbott laboratories, 
Abbott Park, USA) directly after centrifugation. lDl 
cholesterol (lDl-C), non-HDl cholesterol (non-HDl-C), 
and atherogenic index (apoB:apoAI) were calculated. 
Serum samples were divided into small aliquots for 
further assays and frozen at -70°C to avoid peptides 
degradation. Concentration of serum adiponectin and 
visfatin was assayed using available commercial ElISA 
kits (Human Adiponectin RD195023100 BioVendor 
R&D; Visfatin C-Terminal [Human] EK-003-80, Phoenix 
Pharmaceuticals, Inc.). Detection limits were 0.26 ng/ml 
for adiponectin and 0.1 ng/ml for visfatin. All laboratory 
measurements were performed in the Department of 
laboratory Medicine, Nicolaus Copernicus University 
Collegium Medicum in Bydgoszcz, Poland.
Body composition (percentage of body fat, muscle, 
and visceral fat) was evaluated using a body segment 
analyser based on electrical bioimpedance (BIA) tech-
nology (InnerScan V BC-545N, Tanita). Measurements 
were performed in the fasting state, in the morning, 
directly before blood sampling, in accordance with 
the manufacturer’s instructions [7]. The reference 
values of these parameters depended on age, and for 
25–40-year-olds the following values were adopted: fat 
mass in women 21–33%, in men 8–20%; level of visceral 
fat 1–12; muscle mass in women > 24%, in men > 33% 
(according to manufacturer’s manual).
Statistical analysis was performed using STATIS-
TICA 12.0 Pl software (StatSoft, Inc., 2014). Data 
were presented as mean ± standard deviation (nor-
mal distribution) or median and 25th–75th percentile 
(non-Gaussian distribution). Differences between study 
groups were measured by t-Student, U-Mann-Whitney, 
and ANOVA Kruskal-Wallis tests. P values < 0.05 were 
considered statistically significant.
The study was approved by the Bioethics Committee 
at the NCU Collegium Medicum in Bydgoszcz, Poland 
(No. KB 627/2010) and complied with the World Medical 
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Table 1. Clinical characteristics of the study group.





W vs. M 
Age (years) 30 (26–35) 29.5 (25–37) 30 (27–32) ns
BMI (kg/m2) 22.7 ± 2.8 21.3 ± 2.3 24.1 ± 2.7 <0.001
Waist (cm) 80 (69.5–87.5) 70.5 (66–76) 87 (84–94) <0.001
WHR 0.81 (0.75–0.88) 0.75 (0.73–0.79) 0.88 (0.84–0.89) <0.001
SBP (mmHg) 123 ± 11 118 ± 10 129 ± 10 <0.001
DBP (mmHg) 84 ± 8 81 ± 9 86 ± 7 0.036
Fat mass (%) 24.4 ± 6.6 28.2 ± 5.4 20.6 ± 5.4 <0.001
Body mass (%) 51 ± 12.5 40 ± 3.3 61.9 ± 7.7 <0.001
level of visceral fat 4.0 (2.3–6.0) 2.8 (1.5–4.0) 5.75 (4.0–8.0) <0.001
Data presented as mean ± SD or median (25–75%)
ns- statistically insignificant (p > 0.05)
SBP — systolic blood pressure, DBP — diastolic blood pressure
Table 2. Biochemical characteristics of the study group.






Glucose (mg/dl) 92 (88– 96) 89 (85–93) 96 (92–99) <0,001
CRP (mg/l) 0.5 (0.35–1.1) 0.5 (0.4–1.1) 0.6 (0.3–1.2) ns
Insulin (µU/ml) 6.6 (5.1–9.0) 5.95 (5.24–7.36) 7.9 (5.0–10.4) 0.036
HOMA-IR 1.5 (1.1–2.1) 1.32 (1.1–1.6) 1.86 (1.2–2.4) 0.012
TC (mg/dl) 189.6 ± 35.8 186 ± 34 193 ± 38 ns
HDl-C (mg/dl) 55 ± 12 61 ± 11 48 ± 8 <0.001
TG (mg/dl) 82 (65–109) 74 (64–88) 99 (67–127) 0.014
lDl-C (mg/dl) 117 ± 32 109 ± 29 124 ± 33 ns
non- HDl-C (mg/dl) 135 ± 36 125 ± 30 145 ± 39 0.028
apoAI (mg/dl) 145 ± 23 158 ± 21 133 ± 17 <0.001
apoB (mg/dl) 78.0 ± 21 74 ± 16 82.8 ± 22.7 ns
apoB:apoAI 0.56 ± 0.19 0.47 ± 0.12 0.64 ± 0.21 <0.001
Adiponectin (ng/ml) 10 (8–17) 11 (9–17) 8.9 (6.7–16.6) ns
Visfatin (ng/ml) 13 (8.3–22) 15.2 (8.7–26.6) 12 (8.3–19.7) ns
Data presented as mean ± SD or median (25–75%)
ns- statistically insignificant (p>0.05)
Association Declaration of Helsinki regarding ethical 
conduct of research involving human subjects. From 
all participants involved in this study informed written 
consent was collected.
Results
Clinical and biochemical characteristics of the 
study group were presented in Tables 1 and 2. All 
variables showed statistically significant gender dif-
ferences. In women significantly higher percentage of 
fat mass, HDl-cholesterol, and apoAI concentrations 
were found. In men higher values of BMI, WHR, waist 
circumference, blood pressure, and almost twofold 
higher level of visceral fat were observed. In addition 
men showed significantly higher fasting glucose, insulin, 
HOMA-IR, triglycerides, non-HDl-C, and apoB:apoAI. 
Serum adiponectin and visfatin concentrations varied 
at 4.4–29.3 ng/ml and 1.9–36.3 ng/ml, respectively. 
Median adiponectin and visfatin concentrations were 
only slightly higher in women compared to men.
Correlation analysis performed in the whole study 
group showed a significant moderate inverse relation-
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Table 3. Correlation of adiponectin and visfatin with selected variables (R-coefficient values; grey fields — results 
statistically significant p<0.05)
Variables All (n=60) Women (n=30) Men (n=30)
Adiponectin Visfatin Adiponectin Visfatin Adiponectin Visfatin
BMI –0.46 –0.33 –0.35 –0.32 –0.50 –0.37
Waist –0.43 –0.30 –0.46 –0.36 –0.48 –0.41
WHR –0.32 –0.19 –0.22 –0.25 –0.37 –0.20
CRP –0.30 –0.23 –0.46 –0.21 –0.17 –0.24
Insulin –0.34 –0.34 –0.20 –0.28 –0.36 –0.39
HOMA-IR –0.38 –0.34 –0.24 –0.31 –0.41 –0.37
TC –0.13 0.05 0.30 0.32 –0.43 –0.21
lDl-C –0.19 0.01 0.22 0.31 –0.44 –0.24
HDl-C 0.34 0.18 0.33 0.16 0.26 0.21
non-HDl-C –0.22 –0.01 0.22 0.31 –0.46 –0.26
apoAI 0.27 0.13 0.29 0.07 0.14 0.18
Fat mass % –0.48 –0.38 –0.61 –0.33 –0.78 –0.65
Visceral fat –0.68 –0.41 –0.64 –0.42 –0.77 –0.47
Figure 1. Prevalence of subjects in the groups determined by the values of adiponectin and CRP.
ship of adiponectin and visfatin with the percentage of 
fat mass, visceral fat, BMI, and waist circumference, 
whereas the inverse correlation with HOMA-IR and 
insulin was weak (Table 3). 
Adiponectin was weakly inversely related to WHR 
and CRP (R = -0.30; p = 0.022), but a positive correla-
tion was observed with HDl-C (R = 0.34; p=0.009) and 
apoAI (R = 0.27; p = 0.002). 
Visfatin, similarly to adiponectin, showed a weak 
negative correlation with BMI, waist circumference, 
HOMA-IR, and body composition parameters: percent-
age fat mass (R = -0.38; p = 0.003) and visceral fat 
(R = -0.41; p = 0.001). 
In men a stronger relationship of adiponectin and 
visfatin with anthropometric parameters, percentage fat 
mass, and visceral fat was found compared to women. 
Similarly, in men a significant, weak, negative correla-
tion was observed between both adipocytokines and 
HOMA—IR and insulin. Only in men did select lipid 
parameters correlate significantly with adiponectin: 
TC(R = -0.43; p = 0.017), lDl-C (R = -0.44; p=0.015) 
and non-HDl-C (R = -0.46; p = 0.011).
Interestingly, a significant correlation of adiponectin 
with CRP was found only in women (R = -0.46; p = 0.01). 
In further analysis, subjects were divided into three 
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concentrations. For adiponectin, the concentration 
ranges were: 4.43–8.69 (first tertile), 8.70–12.58 (sec-
ond tertile), and 12.59–29.33 (third tertile) ng/ml. 
For visfatin, the distribution in tertiles was as follows: 
1.86–9.58 (first tertile), 9.59–18.86 (second tertile), 
and 18.87–36.29 (third tertile) ng/ml. In subsequent 
adiponectin tertiles, a significant decrease in values of 
BMI (p = 0.02), waist circumference (p = 0.002), level 
of visceral fat (p < 0.001), and insulin concentration 
(p = 0.018) were observed (data not presented). For 
visfatin, similar trends were found only with the level 
of visceral fat (p < 0.01) and triglycerides (p = 0.03). 
With the increase in adiponectin concentration the 
number of subjects with low CRP < 1 mg/l significantly 
rose (p < 0.05; Figure 1). An analogous relationship 
was observed for visfatin (data not presented). More-
over, the highest number of subjects with elevated 
apoB ≥ 100 mg/dl was found at the lowest adiponectin 
concentrations (Figure 2). 
Discussion
The analysis of body composition, especially the 
level of visceral fat, and laboratory markers of chronic 
inflammation, for example adipocytokines, may be 
useful for a more complete assessment of the risk of 
insulin resistance and cardiovascular diseases [8–9]. 
Despite the fact that the problems of obesity and met-
abolic syndrome have been discussed for years, the 
determination of adiponectin, visfatin, and body com-
position are still relatively rarely used in clinical practice 
to assess cardiometabolic risk.
In this study, no significant differences in adiponec-
tin and visfatin concentrations were found for women 
and men; however, median concentrations were slightly 
higher in women. Cnop et al. observed significantly 
higher adiponectin concentrations in women compared 
to men (7.4 ± 2.9 vs. 5.4 ± 2.3 ng/ml; p < 0.001) [10]. 
This phenomenon is explained by a higher percentage 
of adipose tissue in the females.
Yamamoto et al. showed a significant relationship 
between adiponectin levels and the value of arterial 
pressure, while Patel et al. did not observe such 
a correlation [11–12]. Yamamoto et al., in a group of 
967 subjects aged 30–65 years, also found negative 
correlation of adiponectin concentration with BMI, insu-
lin concentration, TC, TG, lDl-C, and insulin resistance 
index HOMA-IR and a positive correlation with HDl 
cholesterol level [ 11]. 
In several studies on obese subject with metabolic 
syndrome a negative correlation was found between adi-
ponectin concentration and waist circumference [13–14], 
as well as with insulin resistance [15]. Interestingly, an 
inverse correlation between adiponectin and CRP was 
observed in a group of 312 men over 50 years of age [16], 
whereas in our study such a correlation was observed 
only in women. Our observation is based on the results 
from a small group of men, which is a limitation of this 
study and could influence the correlation analysis.
Adiponectin concentrations were related most of all 
with the indices of body fat composition, which indicates 
the important role of low concentrations of adiponectin 
in the pathogenesis of obesity, as well as its subsequent 
cardiometabolic complications.
The importance of visfatin in the pathogenesis of 
obesity and metabolic syndrome has not been clearly 
defined so far, and some other studies have yielded 
conflicting results. Fukuhara et al. showed significant 
correlation between visfatin concentration and the 
level of visceral fat and percentage of adipose tissue 
[17], whereas in a study by Berndt et al. no significant 
relationship was found between visfatin concentration 



































Figure 2. Prevalence of subjects in the groups determined by the values of adiponectin and apoB.
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[18]. Others showed a correlation between visfatin 
concentration with waist circumference and diastolic 
blood pressure and no significant dependence on BMI, 
HDl-C, and triglycerides [19]. In our study, moderate 
and weak negative correlations were observed between 
visfatin concentration and BMI, waist circumference, 
HOMA-IR, and, similarly to adiponectin, fat mass and 
level of visceral fat. 
Controversial data in recent years indicate the 
potential role of visfatin in the pathogenesis of ath-
erosclerosis and cardiovascular disease. They show 
that ox-lDl cause an increase in the expression of 
visfatin in cultured monocytes. Its high expression is 
also exhibited by macrophages in unstable athero-
sclerotic plaques; hence, visfatin may play a role in the 
destabilisation of atherosclerotic plaque. Its elevated 
concentrations are observed in groups of patients 
with unstable coronary disease (compared to stable 
disease) and after ischaemic stroke [20]. A study by 
lim et al. conducted on mice showed that after the 
ischaemic event bolus administration of high concen-
tration of visfatin reduced the size of the infarction [21]. 
Therefore, it seems that the increase in blood visfatin 
concentration in atherosclerosis and cardiovascular 
complications may be the result of a compensation 
mechanism associated with the induction of inflam-
mation and vascular damage.
Based on the analysis of prospective popula-
tion-based studies, it was clearly stated that hypoadi-
ponectinaemia is a significant risk factor for cardiovas-
cular disease and metabolic syndrome. In a study of 
577 patients aged 25–74 years, a significant association 
of low adiponectin concentration on cardiovascular 
disease was observed, resulting in a negative effect 
on the metabolism of fatty acids directly involved in 
the development of hypertension [22]. Kumada et al. 
found significantly lower adiponectin level in a group of 
225 men aged 40–69 years after coronarography, com-
pared to the control group (4.7 ng/ml vs. 5.9 ng/ml, 
p < 0.001), which proves that hypoadiponectinaemia 
was significantly and independently associated with 
the onset of ischaemic heart disease (IHD; p < 0.008) 
[23]. In this study, subjects were divided according 
to quartiles of adiponectin concentrations. In the first 
quartile (< 4 ng/ml), the risk of IHD was more than 
2.5-fold higher than in the fourth quartile (> 7 ng/ml), 
regardless of other risk factors (OR = 2.051; CI 95% 
1.288-4.951 vs. OR = 0.749; 95% CI 0.392-1.418). 
Mohan et al. showed that adiponectin levels were 
significantly lower in patients with MetS compared to 
the control group (men: 5.0 vs. 6.8 ng / ml; p = 0.01; 
women: 6.5 vs. 9.9 ng/ml; p = 0.001). The analysis of 
the relationship showed a strong negative relationship 
between the concentration of adiponectin and the prob-
ability of the onset of metabolic syndrome in the study 
group (p < 0.001) [24]. In our study, the highest preva-
lence of subject with CRP < 1 mg/l, which reflects low 
relative risk of cardiovascular disease, was observed in 
the third adiponectin tertile, while an increased number 
of subjects with elevated apoB ≥ 100 mg/dl was found 
in the first tertile. This might indicate that in apparently 
healthy, non-obese individuals low adiponectin levels 
are associated with low-grade inflammation and dyslip-
idaemia, which increases cardiometabolic risk.
Considering the results of our own study and the 
presented relationships between adiponectin and 
visfatin concentration with select parameters of body 
composition, as well as biochemical risk factors for 
metabolic syndrome and cardiovascular diseases, it 
seems that the determination of these adipocytokines 
may be clinically useful in the more accurate assess-
ment of possible cardiometabolic disorders in young, 
healthy people. However, due to the limitation of the 
study (small study group) the predictive value of both 
adipocytokines should be confirmed in a large popu-
lation-based study.
Authors’ conflict of interest disclosure: The 
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